Search

Search Constraints

You searched for: Author/Creator Chollet, Philippe

Search Results

1. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Issue 1 (July 2015)

2. Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial. Issue 10 (10th December 2020)

3. Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer. (30th January 2015)

4. Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response‐Guided and Standard Treatments in HER2‐Negative Operable Breast Cancer. (30th January 2015)

5. Long‐term Significance (15 years) of Pathological Complete Response after Dose‐dense Neoadjuvant Chemotherapy in Breast Cancer. Issue 4 (11th June 2013)

6. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer. (5th March 2021)

7. Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. (22nd April 2020)